anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Frailty is a health condition linked to adverse health outcomes and lower life quality. The PRISMA-7, a 7-item questionnaire from the Program on Research for Integrating Services for the Maintenance of Autonomy (PRISMA), is a validated case-finding tool for frailty with good sensitivity and specificity. This study aimed to translate, culturally adapt, and validate the PRISMA-7 questionnaire for Chinese use.
METHODS: A prospective observational study with convenience sampling recruited bilingual adults aged 65 and over living in the community. The Functional Autonomy Measurement System (SMAF) was the gold standard benchmark. The English PRISMA-7 questionnaire was culturally adapted to Chinese using forward and backward translation. Intra- and inter-rater reliability were determined using the intraclass correlation coefficient (ICC). Face, content and criterion validity were determined. The Receiver Operator characteristic (ROC) curve determined the optimal cut-off score.
RESULTS: One-hundred-twenty participants (55 females and 65 males) were recruited. The Chinese PRISMA-7 questionnaire had excellent intra-rater and inter-rater reliability (ICC = 1.000). The rigorous forward and backward translation established the face and content validity. The moderately high correlations between the English PRISMA-7 with SMAF (r = - 0.655, p <  0.001) and Chinese PRISMA-7 with SMAF (r = - 0.653, p <  0.001) pairs established the criterion validity. An optimal cut-off score of three "Yes" responses was reported with 100% sensitivity and 85.3% specificity.
CONCLUSION: This translation, cross-cultural adaptation, and validation study established the Chinese PRISMA-7 questionnaire. The preliminary results suggest adequate diagnostic test accuracy for frailty screening among the Chinese-literate community.
Parodontosis prophylactic device which enables air to be circulated in the gaps between the teeth to destroy anaerobic bacteria is claimed.  The device is made e.g. from a preferably elastic grid-, spiral- or skeletal form material in the shape of a tube, roll or sheet which may be cut to length or supplied in long lengths from which pieces of desired length can be cut. The material is positioned in the mouth to lie between the teeth and the lips or cheeks to allow air access. The device is preferably fabricated as a disposable item and is made e.g. from plant-based raw materials, especially impregnated paper fibres. The device may be used as a carrier for a medicinal agent.
GATA binding protein 2 (GATA2) is a conserved zinc finger transcription factor that regulates the emergence and maintenance of complex genetic programs driving development and function of hematopoietic stem and progenitor cells (HSPCs). Patients born with monoallelic GATA2 mutations develop myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML), whereas acquired GATA2 mutations are reported in 3% to 5% of sporadic AML cases. The mechanisms by which aberrant GATA2 activity promotes MDS and AML are incompletely understood. Efforts to understand GATA2 in basic biology and disease will be facilitated by the development of broadly efficacious antibodies recognizing physiologic levels of GATA2 in diverse tissue types and assays. Here, we purified a polyclonal anti-GATA2 antibody and generated multiple highly specific anti-GATA2 monoclonal antibodies, optimized them for immunohistochemistry on patient bone marrow bioosy samples, and analyzed GATA2 expression in adults with healthy bone marrow, MDS, and acute leukemia. In healthy bone marrow, GATA2 was detected in mast cells, subsets of CD34+ HSPCs, E-cadherin-positive erythroid progenitors, and megakaryocytes. In MDS, GATA2 expression correlates with bone marrow blast percentage, positively correlates with myeloid dysplasia and complex cytogenetics, and is a nonindependent negative predictor of overall survival. In acute leukemia, the percent of GATA2+ blasts closely associates with myeloid lineage, whereas a subset of lymphoblastic and undifferentiated leukemias with myeloid features also express GATA2. However, the percent of GATA2+ blasts in AML is highly variable. Elevated GATA2 expression in AML blasts correlates with peripheral neutropenia and complex AML cytogenetics but, unlike in MDS, does not predict survival.
PROBLEM TO BE SOLVED: To obtain a skin whitening cosmetic which not only inhibits the production of melanin caused by the lesion due to ultraviolet rays but also promotes the excretion of melanin pigment and particularly exerts excellent skin whitening effect. SOLUTION: This skin whitening cosmetic contains both an extract from the fruit of Chinese name 'HUOASHI' (firethorn) of one kind belonging to the genus Pyracantha of the family Rosaceae and N-methyl-L-serine. The active ingredient contained in the Chinese herbal medicine 'CHIHYANSU' of the fruit of Chinese name 'HUOASHI' used on this invention is extracted with water, a lower alcohol, e.g. methanol, ethanol, propanol or the like, or their mixture. The active ingredient is preferably blended in a proportion of 0.0001-5 wt.% based on the whole weight of the cosmetic in terms of powder containing in the extract, but the compound amount is not restricted to the above proportion. N-Methyl-L-serine used on this invention is a widely known compound.  It is preferably blended in a proportion of 0.001-3 wt.% based on the whole weight of the cosmetic, but the compound amount is not restricted to the above proportion.
Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
PURPOSE: To obtain Acanthamoeba deactivator containing, as active ingredient, a compound having specific structure, having excellent Acanthamoeba cyst removal-inhibitory action and amebicidal action, thus useful as e.g. Acanthamoeba contamination inhibitor. CONSTITUTION: This Acanthamoeba deactivator contains, as active ingredient, a 4-substituted resorcinol derivative of the formula (R is a straight chain or branched alkyl) (pref. 4-ethylresorcinol or 4-hexylresorcinol). When this deactivator is to be used in the form of cold sterilizing solution for contact lens, it is recommended that contact lens be immersed at room temperature for 10-15min in a polyhydric alcohol solution containing 0.2-2w/v% of the compound of the formula. When this deactivator is to be used as a preventive or therapeutic agent for amebic keratitis etc., it is preferable that this deactivator, in the form of eye drop, be administered at one to several droplets at a time three to four times a day.
Compounds of insulin and nucleic acids (nucleotides) described as insulin nucleotidates are prepared by mixing a dilute solution of insulin with a dilute alkaline solution of a nucleotide and precipitating the compound by the addition of acid.  The preparation of compounds of insulin with several nucleic acids, e.g. yeast nucleic acid, thymus gland nuclei acid is described. For injection purposes the insulin nucleate is dissolved in dilute alkali and neutralized to give a neutral or faintly alkaline solution.ALSO:Compounds of insulin and nucleic acids (nucleotides) described as insulin nucleotidates are prepared by mixing a dilute solution of insulin with a dilute alkaline solution of a nucleotide and precipitating the compound by the addition of acid.  The preparation of compounds of insulin with several nucleic acids, e.g. yeast nucleic acid, thymus gland nucleic acid is described. For injection purposes the insulin nucleate is dissolved in dilute alkali and neutralized to give a neutral or faintly alkaline solution.
BACKGROUND: Several studies report lack of meropenem pharmacokinetic/pharmacodynamic (PK/PD) target attainment (TA) and risk of therapeutic failure with intermittent bolus infusions in intensive care unit (ICU) patients. The aim of this study was to describe meropenem TA in an ICU population and the clinical response in the first 72 h after therapy initiation.
METHODS: A prospective observational study of ICU patients ≥18 years was conducted from 2014 to 2017. Patients with normal renal clearance (NRC) and augmented renal clearance (ARC) and patients on continuous renal replacement therapy (CRRT) were included. Meropenem was administered as intermittent bolus infusions, mainly at a dose of 1 g q6h. Peak, mid, and trough levels were sampled at 24, 48, and 72 h after therapy initiation. TA was defined as 100% T > 4× MIC or trough concentration above 4× MIC. Meropenem PK was estimated using traditional calculation methods and population pharmacokinetic modeling (P-metrics®). Clinical response was evaluated by change in C-reactive protein (CRP), Sequential Organ Failure Assessment (SOFA) score, leukocyte count, and defervescence.
RESULTS: Eighty-seven patients were included, with a median Simplified Acute Physiology (SAPS) II score 37 and 90 days mortality rate of 32%. Median TA was 100% for all groups except for the ARC group with 45.5%. Median CRP fell from 175 (interquartile range [IQR], 88-257) to 70 (IQR, 30-114) (p < .001) in the total population. A reduction in SOFA score was observed only in the non-CRRT groups (p < .001).
CONCLUSION: Intermittent meropenem bolus infusion q6h gives satisfactory TA in an ICU population with variable renal function and CRRT modality, except for ARC patients. No consistent relationship between TA and clinical endpoints were observed.
Neonate \>2500g and born with a gestation age \>37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 \& 6 weeks post-op and attend all scheduled follow up appointments.
It has been found that agents which inhibit the interaction between the band 3 protein and its ligand (hereafter sometimes referred to as "interaction inhibitors" or "inhibitors"), CD36/thrombospondin, can also be used to enhance thrombolysis. The inhibitors can be peptides which contain sequences present in exofacial loops of the band 3 protein, or can be non-natural, D-isomer forms of the same sequences, or can be peptides, peptidomimetics, or non-peptidic molecules which interfere with band 3 protein-ligand interactions. One preferred group of such inhibitors comprises peptides characterized by the sequence motifZ2Z3Z2UX-UUUX- (SEQ ID NO:44),wherein Z2 represents a hydrophobic residue, U represents unobstructive residues, Z3 is either Z2 or an unobstructive residue and X- represents negatively charged residues. Another preferred group of such inhibitors comprises peptides characterized by the sequence motifZ1UKUUUX+ (SEQ ID NO:45),wherein Z1 is selected from the group consisting of tyrosine, phenylalanine and alanine; K is a lysine residue; U represents unobstructive residues; and X+ is a positively charged residue. The reverse sequences of these peptides are also active. The inhibitors of the subject method can be administered alone or in combination with one or more additional therapeutic agents. Administration can be oral, intravenous or by other means, in amounts between about 0.1 mg/kg to about 20 mg/kg.
The present invention discloses a marked Pestivirus suis C strain expressing enhanced green fluorescent protein and construction method and application thereof, and belongs to construction and application of marked Pestivirus suis C strain. A C strain infectious clone is used as a skeleton, the Pestivirus suis Shimen strain Npro protein is used to substitute a C strain Npro protein, then an EGFP gene is introduced between No. 13 and 14 amino acids of the Npro protein to obtain an marked Pestivirus suis C strain expressing enhanced green fluorescent protein, wherein the strain has microbial preservation number: CGMCC No. 12039. The marked Pestivirus suis C strain can stably express EGFP gene, is successfully observed with green fluorescence, retains biological properties and immunogenicity of the parental viruses, and can be applied to the preparation of marked vaccines for prevention of Pestivirus suis. The present invention confirms that the C strain Npro protein can be modified to obtain marked Pestivirus suis, so as to lay foundation for the development of marked C strain vaccine.
80 adult patients (40 women, 40 men) scheduled to undergo elective surgical procedures requiring general anesthesia and necessitating endotracheal intubation, were included in this study. Patients eligible for participation were aged 18-60 yrs., ASA physical status I or II and BMI \< 30 kg/m2. Before anesthesia induction, CP was verified as follow: the cricoid cartilage was first identified and then held between the thumb and middle finger and the pressure was applied by the index finger with a force that could be tolerated by the patient. After loss of consciousness, four predetermined forces: 0 , 10 , 20 and 30 N were chosen in a randomized method. Therefore, after applying the predetermined force, a GT 20 F insertion trial was performed and two outcomes were considered: 1) Failure of GT insertion: effective CP. The next trials were not attempted. 2) Success of GT insertion: ineffective CP. The patient received a second attempt with increasing force to the next scale of force. If the attempt was effective (failure of GT insertion) , the relevant force is considered as the effective CP force. Same trial was repeated using 0, 10, 20 and 30 N respectively in in a randomized fashion for each patient. The cricoid force was standardized by reproducing 10, 20 and 30 N on a weighing scale prior to each application.

Four anesthesia providers (operators) participated in the study: The first operator performed CP in all patients with his back towards the video monitor; the second operator performed laryngoscopy using GVL and GT insertion trials and he was not aware about the nature of study ; the third operator assessed the effectiveness of the applied CP and determined the position of the esophageal entrance in relation to the glottis. The fourth operator, who was standing behind the second operator, signaled to the second operator to start attempt for each trial with the predetermined CP forces and to the first operator who applying CP to stop or continue accordingly.

In order to "blind" the second operator, a screen separated the laryngoscopist and the first operator applying CP, while the hand position for the CP was maintained, even when CP was not applied. Data collected before staring surgery.
The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
ABSTRACT          Double salt, process for its preparation and pharmaceutical composition containing it.      The double sulfate of 1-desoxy-(5-hydroxytryptamino)-D-fructose (DFS) and 1-methylhydantoin-2-imide (creatinine) represents a new solid crystalline phase of unit composition, pharmaceutical quality and remarkable stability.     It is prepared by glycosylation of serotonin with D-glucose, formation of the double salt by addition of sulfuric acid and creatinine and crystallization of the double salt in the presence of ethanol.  The DFS is preferably isolated from the reaction medium by way of the addition complex DFS.Ca(OH)2 which is precipitated by the addition of calcium hydroxide.   The calcium hydroxide is then eliminated by addition of sulfuric acid and the double salt crystallized as described above.     The DFS is the active principle of a medicament effective in particular in the treatment of leprosy.
PURPOSE OF REVIEW: Several novel therapies approved by the Food and Drug Administration (FDA) and explosion of clinical trials have changed the landscape Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC). Given the recent advancements in bladder sparing options, the role of radical cystectomy (RC) in BCG-unresponsive NMIBC remains a subject of debate.
RECENT FINDINGS: All three novel agents currently approved by the FDA for BCG-unresponsive NMIBC have strict indication [carcinoma in situ (CIS)], low response rate, and short response duration. Some promising new agents are awaiting results and/or FDA approval. RC still provides the best oncologic control and acceptable quality of life, and potentially represents the most cost-effective option.
SUMMARY: It is an exciting time for the urologic oncology community to see the FDA approvals of some of the novel bladder sparing therapies and expansion of ongoing clinical trials. Yet, RC should still be considered as the gold standard of BCG-unresponsive NMIBC. We also must be cautious and selective in recommending bladder sparing options for patients with BCG-unresponsive NMIBC.
Hereditary Cancer makes up around 5-10% of all cancers. It is important to diagnose hereditary cancer in a timely fashion, as not only do patients require long-term care from a young age, but their relatives also require management. The main approach to capture at-risk relatives is cascade testing. It involves genetic testing of relatives of the first detected carrier of a pathogenic variant in a family i.e. the proband. The current standard of care for cascade testing is a patient-mediated approach. Probands are then advised to inform and encourage family members to undergo genetic testing. In Singapore, cascade testing is inefficient, around 10-15%, lower than the 30% global average. Here, we describe the cascade testing process and its effort to increase testing in Singapore. Precision Health Research, Singapore (PRECISE), was set up to coordinate Singapore's National Precision Medicine strategy and has awarded five clinical implementation pilots, with one of them seeking to identify strategies for how cascade testing for hereditary cancer can be increased in a safe and cost-efficient manner. Achieving this will be done through addressing barriers such as cost, manpower shortages, exploring a digital channel for contacting at-risk relatives, and getting a deeper insight into why genetic testing gets declined. If successful, it will likely result in care pathways that are a cost-effective public health intervention for identifying individuals at risk. Surveillance and management of those unaffected at-risk individuals, if caught early, will result in improved patient outcomes, and further reduce the healthcare burden for the economy.
Sequence of short gentle moves are applied over Hamstrings.Skin slack is taken to lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are be given for 4 weeks. The treatment time for each session is 20 minutes.
Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease \[MDRD\] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
The emergence of highly infectious pathogens with their potential for triggering global pandemics necessitate the development of effective treatment strategies, including broad-spectrum antiviral therapies to safeguard human health. This study investigates the antiviral activity of emetine, dehydroemetine (DHE), and congeneric compounds against SARS-CoV-2 and HCoV-OC43, and evaluates their impact on the host cell. Concurrently, we assess the potential cardiotoxicity of these ipecac alkaloids. Significantly, our data reveal that emetine and the (-)-R,S isomer of 2,3-dehydroemetine (designated in this paper as DHE4) reduce viral growth at nanomolar concentrations (i.e., IC50 ∼ 50-100 nM), paralleling those required for inhibition of protein synthesis, while calcium channel blocking activity occurs at elevated concentrations (i.e., IC50 ∼ 40-60 µM). Our findings suggest that the antiviral mechanisms primarily involve disruption of host cell protein synthesis and is demonstrably stereoisomer specific. The prospect of a therapeutic window in which emetine or DHE4 inhibit viral propagation without cardiotoxicity renders these alkaloids viable candidates in strategies worthy of clinical investigation.
Pancreatic cancer is the fourth leading cause of cancer death in both men and women in the United States. In 2015, there were 49,000 new diagnoses with 41,000 deaths . A recent analysis of the pedigrees in the National Familial Pancreatic Tumor Registry found that individuals with a family history of pancreatic cancer in first-degree relatives are at an increased risk of developing pancreatic cancer themselves. There are more than a dozen inherited germline mutations that increase the risk of pancreatic cancer in these family members. In an attempt to lower the number of individuals that develop advanced pancreatic cancer, an early-detection program is created to detect tumors at a stage early enough that treatment is likely to be successful. Numerous treatment options exist such as surveillance, radiation therapy, systemic therapy and surgery. Determining which treatment option will be implemented is based on the stage and grade of the tumor/cancer.
The invention belongs to the field of Chinese medicaments, in particular to the field of Chinese medicaments for treating facial nerve diseases. The powder for treating nerve refractory diseases comprises the following Chinese medicinal components by mass: 3 to 8g of nux vomica and 1 to 3g of manchurian wildginger. The method for preparing the powders comprises the following steps: cutting the manchurian wildginger to pieces, putting the cut manchurian wildginger into a cup, and adding 50ml of water into the cup; and then putting the nux vomica into the cup, immersing the nux vomica until thenux vomica becomes soft, cutting the soft nux vomica into 1.5mm of slices along a diameter direction, and airing the slices for later use. The medicament has the effect of dispersing swelling and relieving pain, and mainly treats facial nerve paralysis and swelling pain. For 162 cases of the facial paralysis, 130 cases are cured and accounts for 80.25 percent, 16 cases achieve remarkable effect and accounts for 9.88 percent, 11 cases are improved and accounts for 6.79 percent and 6 cases do not achieve effect and accounts for 3.08 percent. The total effective rate reaches 96.92 percent.